Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05555732




Registration number
NCT05555732
Ethics application status
Date submitted
22/09/2022
Date registered
27/09/2022
Date last updated
12/11/2024

Titles & IDs
Public title
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Scientific title
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Secondary ID [1] 0 0
2022-500802-16-00
Secondary ID [2] 0 0
DS1062-A-U303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Non Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Datopotamab Deruxtecan
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin

Experimental: Dato-DXd + Pembrolizumab + Platinum Chemotherapy - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).

Experimental: Dato-DXd + Pembrolizumab - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.

Active comparator: Pembrolizumab + Pemetrexed + Platinum Chemotherapy - Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).


Treatment: Drugs: Datopotamab Deruxtecan
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Pemetrexed
Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Carboplatin
Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Treatment: Drugs: Cisplatin
Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival Based on Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [1] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Primary outcome [2] 0 0
Overall Survival in Participants in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [2] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [1] 0 0
Objective Response Rate by Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [1] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [2] 0 0
Progression-free Survival by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [2] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [3] 0 0
Objective Response Rate by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [3] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [4] 0 0
Duration of Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [4] 0 0
From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 29 months
Secondary outcome [5] 0 0
Time to Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [5] 0 0
From randomization to date of first objective response (CR or PR), up to approximately 29 months
Secondary outcome [6] 0 0
Disease Control Rate by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [6] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [7] 0 0
Progression-free Survival 2 in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [7] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [8] 0 0
Time to Deterioration in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [8] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [9] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAE) in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [9] 0 0
Up to 57 months
Secondary outcome [10] 0 0
Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA
Timepoint [10] 0 0
Baseline and up to 57 months

Eligibility
Key inclusion criteria
Key

1. Sign and date the Main ICF, prior to the start of any study- specific qualification procedures. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
2. Adults =18 at the time the Main ICF is signed. (Follow local regulatory requirements if the legal age of adult voluntary consent for study participation is >18 years old).
3. Has tumor with PD-L1 TPS <50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing (minimum of six slides). PD-L1 expression results available at the same central laboratory from screening for the purpose of entry into another Dato-DXd study may be used for tissue screening purposes in this study as long as the subject has not been randomized/enrolled in the other study.
4. Has provided a formalin-fixed tumor tissue sample (minimum of 4 × 4-micron sections or block equivalent) for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected, and the subject is still eligible for the study.
5. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Subjects who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criteria are eligible if the adjuvant/ neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease and should not have progressed on or within the 6 months of completion.
6. Has measurable disease based on local imaging assessment using RECIST v1.1; radiographic tumor assessment must be performed within 28 days before randomization.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Has received prior systemic treatment for advanced/metastatic NSCLC.
2. Has received prior treatment with any of the following, including in the adjuvant/neoadjuvant setting (for NSCLC):

1. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I
2. TROP2-targeted therapy
3. Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137)
4. Any other ICIs Subjects who received adjuvant or neoadjuvant therapy OTHER than those listed above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease.
3. Has received a live vaccine within 30 days prior to the first dose of study treatment.

Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. For any subject receiving an approved severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine, please follow the vaccine label and/or local guidance. The vaccine manufacturer and the date of administration should be recorded on the electronic case report form (Concomitant Medications page), as should any AEs relating to the vaccine (including hypersensitivity or allergies). Note: Any licensed SARS-CoV2 vaccine (including those authorized for emergency use) in a particular country is allowed in the study as long as the vaccine is an mRNA vaccine, replication-incompetent adenoviral vaccine, or inactivated vaccine. Such vaccines will be treated just as any other concomitant therapy.

Investigational vaccines (ie, those not licensed or authorized for emergency use) are not allowed.
4. Has spinal cord compression or clinically active untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 2 weeks by repeat imaging (Note: Repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days before the first dose of study drug. Note: A contrasted computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain at baseline (MRI with contrast preferred) is required for all subjects. For those subjects in whom CNS metastases are first discovered at the time of screening, the treating investigator must delay of study treatment to document stability of CNS metastases with repeat imaging at least 2 weeks later (in which case, repeat of all screening activity may be required).
5. Has uncontrolled or significant cardiovascular disease not controlled by maximal medical therapy, including:

1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval >470 msec regardless of sex (based on the 12-lead electrocardiogram [ECG] performed at screening).
2. Myocardial infarction within 6 months prior to Cycle 1 Day 1.
3. History of a serious cardiac arrhythmia requiring treatment
4. Uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1.
5. Left ventricular ejection fraction (LVEF) <50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization.
6. New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) at screening. Subjects with a history of Class II to IV CHF prior to screening, must have returned to Class I CHF and have LVEF =50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible.
7. Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).
6. Clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli diagnosed within 3 months of Cycle 1 Day 1, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc) or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc), or prior complete pneumonectomy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2027
Actual
Sample size
Target
1170
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CRSA/ St Andrews Hospital - Adelaide
Recruitment hospital [2] 0 0
Flinders Medical Centre (Fmc) - Bedford Park
Recruitment hospital [3] 0 0
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group) - Frankston
Recruitment hospital [4] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment hospital [5] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
2500 - Wollongong
Recruitment postcode(s) [5] 0 0
QLD 4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma de Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Autonoma de Buenos Aire
Country [17] 0 0
Argentina
State/province [17] 0 0
Mar del Plata
Country [18] 0 0
Argentina
State/province [18] 0 0
Pergamino
Country [19] 0 0
Argentina
State/province [19] 0 0
Rosario
Country [20] 0 0
Argentina
State/province [20] 0 0
San Juan
Country [21] 0 0
Argentina
State/province [21] 0 0
Viedma
Country [22] 0 0
Austria
State/province [22] 0 0
Feldkirch
Country [23] 0 0
Austria
State/province [23] 0 0
Klagenfurt
Country [24] 0 0
Austria
State/province [24] 0 0
Vienna
Country [25] 0 0
Belgium
State/province [25] 0 0
Gent
Country [26] 0 0
Belgium
State/province [26] 0 0
Haine Saint-Paul
Country [27] 0 0
Belgium
State/province [27] 0 0
Ottignies
Country [28] 0 0
Belgium
State/province [28] 0 0
Sint-Niklaas
Country [29] 0 0
Brazil
State/province [29] 0 0
Belo Horizonte
Country [30] 0 0
Brazil
State/province [30] 0 0
Caxias do Sul
Country [31] 0 0
Brazil
State/province [31] 0 0
Curitiba
Country [32] 0 0
Brazil
State/province [32] 0 0
Ijui
Country [33] 0 0
Brazil
State/province [33] 0 0
ItajaA-
Country [34] 0 0
Brazil
State/province [34] 0 0
Pelotas
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio de Janeiro
Country [37] 0 0
Brazil
State/province [37] 0 0
Santo Andre
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Paulo
Country [39] 0 0
Brazil
State/province [39] 0 0
Taubate
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec City
Country [41] 0 0
Chile
State/province [41] 0 0
Santiago de Chile
Country [42] 0 0
Chile
State/province [42] 0 0
Santiago
Country [43] 0 0
Chile
State/province [43] 0 0
ViAaa Del Mar
Country [44] 0 0
China
State/province [44] 0 0
Beijing Sheng
Country [45] 0 0
China
State/province [45] 0 0
Beijing
Country [46] 0 0
China
State/province [46] 0 0
Cangzhou
Country [47] 0 0
China
State/province [47] 0 0
Changchun
Country [48] 0 0
China
State/province [48] 0 0
Changsha
Country [49] 0 0
China
State/province [49] 0 0
Chengdu
Country [50] 0 0
China
State/province [50] 0 0
Chongqing
Country [51] 0 0
China
State/province [51] 0 0
Fuzhou
Country [52] 0 0
China
State/province [52] 0 0
Guangzhou
Country [53] 0 0
China
State/province [53] 0 0
Hangzhou
Country [54] 0 0
China
State/province [54] 0 0
Harbin
Country [55] 0 0
China
State/province [55] 0 0
Hefei
Country [56] 0 0
China
State/province [56] 0 0
Hohhot
Country [57] 0 0
China
State/province [57] 0 0
Jiamusi
Country [58] 0 0
China
State/province [58] 0 0
Linyi
Country [59] 0 0
China
State/province [59] 0 0
Nanchang
Country [60] 0 0
China
State/province [60] 0 0
Nanjing
Country [61] 0 0
China
State/province [61] 0 0
Shanghai
Country [62] 0 0
China
State/province [62] 0 0
Shenyang
Country [63] 0 0
China
State/province [63] 0 0
Wuhan
Country [64] 0 0
China
State/province [64] 0 0
Xi'an
Country [65] 0 0
China
State/province [65] 0 0
Xianyang
Country [66] 0 0
China
State/province [66] 0 0
Zhengzhou
Country [67] 0 0
China
State/province [67] 0 0
Ürümqi
Country [68] 0 0
France
State/province [68] 0 0
Bordeaux
Country [69] 0 0
France
State/province [69] 0 0
France
Country [70] 0 0
France
State/province [70] 0 0
Lyon
Country [71] 0 0
France
State/province [71] 0 0
Marseille Cedex 20
Country [72] 0 0
France
State/province [72] 0 0
Montpellier Cedex 5
Country [73] 0 0
France
State/province [73] 0 0
Nantes
Country [74] 0 0
France
State/province [74] 0 0
Paris
Country [75] 0 0
France
State/province [75] 0 0
Suresnes
Country [76] 0 0
Germany
State/province [76] 0 0
Berlin
Country [77] 0 0
Germany
State/province [77] 0 0
Chemnitz
Country [78] 0 0
Germany
State/province [78] 0 0
Essen
Country [79] 0 0
Germany
State/province [79] 0 0
Esslingen
Country [80] 0 0
Germany
State/province [80] 0 0
Giessen
Country [81] 0 0
Germany
State/province [81] 0 0
Mannheim
Country [82] 0 0
Germany
State/province [82] 0 0
Muenster
Country [83] 0 0
Germany
State/province [83] 0 0
Munich
Country [84] 0 0
Greece
State/province [84] 0 0
Athens
Country [85] 0 0
Greece
State/province [85] 0 0
Heraklion
Country [86] 0 0
Greece
State/province [86] 0 0
Ioannina
Country [87] 0 0
Greece
State/province [87] 0 0
Neo Faliro
Country [88] 0 0
Greece
State/province [88] 0 0
Thessalonki
Country [89] 0 0
Hong Kong
State/province [89] 0 0
Hong Kong
Country [90] 0 0
Hong Kong
State/province [90] 0 0
Pok Fu Lam
Country [91] 0 0
Hungary
State/province [91] 0 0
Budapest
Country [92] 0 0
Hungary
State/province [92] 0 0
Farkasgyepu
Country [93] 0 0
Hungary
State/province [93] 0 0
KecskemAŠt
Country [94] 0 0
Hungary
State/province [94] 0 0
Szekesfehervar
Country [95] 0 0
Hungary
State/province [95] 0 0
Szolnok
Country [96] 0 0
Italy
State/province [96] 0 0
Candiolo
Country [97] 0 0
Italy
State/province [97] 0 0
Lucca
Country [98] 0 0
Italy
State/province [98] 0 0
Orbassano
Country [99] 0 0
Italy
State/province [99] 0 0
Rome
Country [100] 0 0
Italy
State/province [100] 0 0
Udine
Country [101] 0 0
Italy
State/province [101] 0 0
Varese
Country [102] 0 0
Italy
State/province [102] 0 0
Verona
Country [103] 0 0
Japan
State/province [103] 0 0
Ehime
Country [104] 0 0
Japan
State/province [104] 0 0
Fukoka
Country [105] 0 0
Japan
State/province [105] 0 0
Fukuoka
Country [106] 0 0
Japan
State/province [106] 0 0
Hokkaido
Country [107] 0 0
Japan
State/province [107] 0 0
Hyogo
Country [108] 0 0
Japan
State/province [108] 0 0
Ishikawa
Country [109] 0 0
Japan
State/province [109] 0 0
Kanagawa
Country [110] 0 0
Japan
State/province [110] 0 0
Kumamoto
Country [111] 0 0
Japan
State/province [111] 0 0
Kyoto
Country [112] 0 0
Japan
State/province [112] 0 0
Mie
Country [113] 0 0
Japan
State/province [113] 0 0
Miyagi
Country [114] 0 0
Japan
State/province [114] 0 0
Niigata
Country [115] 0 0
Japan
State/province [115] 0 0
Osaka
Country [116] 0 0
Japan
State/province [116] 0 0
Tochigi
Country [117] 0 0
Japan
State/province [117] 0 0
Tokyo
Country [118] 0 0
Japan
State/province [118] 0 0
Yamaguchi
Country [119] 0 0
Japan
State/province [119] 0 0
Yamanashi
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Cheongjusi
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Daegu
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Gangnam-Gu
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Goyang-si
Country [124] 0 0
Korea, Republic of
State/province [124] 0 0
Jinju-si Gyeongsangnam-do
Country [125] 0 0
Korea, Republic of
State/province [125] 0 0
Seongnam-si
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Seoul
Country [127] 0 0
Mexico
State/province [127] 0 0
Cuauhtemoc
Country [128] 0 0
Mexico
State/province [128] 0 0
Guadalajara
Country [129] 0 0
Mexico
State/province [129] 0 0
Oaxaca
Country [130] 0 0
Netherlands
State/province [130] 0 0
Breda
Country [131] 0 0
Netherlands
State/province [131] 0 0
Leiden
Country [132] 0 0
Netherlands
State/province [132] 0 0
s-Hertogenbosch
Country [133] 0 0
Poland
State/province [133] 0 0
Bialystok
Country [134] 0 0
Poland
State/province [134] 0 0
Lodz
Country [135] 0 0
Poland
State/province [135] 0 0
Lublin
Country [136] 0 0
Poland
State/province [136] 0 0
Poznan
Country [137] 0 0
Romania
State/province [137] 0 0
Cluj- Napoca
Country [138] 0 0
Romania
State/province [138] 0 0
Craiova
Country [139] 0 0
Romania
State/province [139] 0 0
Timisoara
Country [140] 0 0
Spain
State/province [140] 0 0
Barcelona
Country [141] 0 0
Spain
State/province [141] 0 0
Lleida
Country [142] 0 0
Spain
State/province [142] 0 0
Madrid
Country [143] 0 0
Spain
State/province [143] 0 0
Malaga
Country [144] 0 0
Spain
State/province [144] 0 0
Ourense
Country [145] 0 0
Spain
State/province [145] 0 0
Sevilla
Country [146] 0 0
Spain
State/province [146] 0 0
Valenica
Country [147] 0 0
Spain
State/province [147] 0 0
Zaragoza
Country [148] 0 0
Switzerland
State/province [148] 0 0
Liestal
Country [149] 0 0
Switzerland
State/province [149] 0 0
St. Gallen
Country [150] 0 0
Switzerland
State/province [150] 0 0
Thun
Country [151] 0 0
Taiwan
State/province [151] 0 0
Hsia
Country [152] 0 0
Taiwan
State/province [152] 0 0
Taipei
Country [153] 0 0
Thailand
State/province [153] 0 0
Bangkok
Country [154] 0 0
Thailand
State/province [154] 0 0
Chiang Mai
Country [155] 0 0
Thailand
State/province [155] 0 0
Hat Yai
Country [156] 0 0
Thailand
State/province [156] 0 0
Mueang Nonthaburi
Country [157] 0 0
Turkey
State/province [157] 0 0
Adana
Country [158] 0 0
Turkey
State/province [158] 0 0
Seyhan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
AstraZeneca
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Trial website
https://clinicaltrials.gov/study/NCT05555732
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Daiichi Sankyo Contact for Clinical Trial Information
Address 0 0
Country 0 0
Phone 0 0
908-992-6400
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05555732